CRISPR
CRISPR.......................................................................................................................................................... 1
OVERVIEW.................................................................................................................................................... 2
CONCEPT BEHIND CRISPR/CAS:..............................................................................................................................2
TYPICAL STRUCTURE...............................................................................................................................................3
STAGES OF THE CRISPR/CAS SYSTEM............................................................................................................. 4
STAGE 1: SPACER ACQUISITION (IMMUNIZATION/ADAPTATION).....................................................................................4
Protospacers & PAM:......................................................................................................................................4
STAGE 2: CRNA EXPRESSION & PROCESSING..............................................................................................................5
STAGE 3: CRISPR INTERFERENCE (TARGETING/IMMUNITY)...........................................................................................5
MECHANISMS OF ACTION............................................................................................................................. 7
TYPE II SYSTEM CRISPR/CAS 9...............................................................................................................................7
Spacer Acquisition..........................................................................................................................................7
cRNA expression & processing........................................................................................................................7
CRISPR Interference/Targeting.......................................................................................................................7
GENOME EDITING......................................................................................................................................... 9
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza...............................9
Guide RNA – sgRNA........................................................................................................................................9
CRISPR/CAS NUCLEASE RNA-GUIDED GENOME EDITING USING NHEJ.........................................................................10
CRISPR/CAS NUCLEASE RNA-GUIDED GENOME EDITING USING HDR FOR GENE INSERTIONS...........................................10
CRISPR/CAS GENE REGULATION...........................................................................................................................11
Transcription repression...............................................................................................................................11
Transcription activation................................................................................................................................11
ADVANTAGES OF CRISPR/CAS 9 AS A GENOME-EDITING TOOL....................................................................................11
, CRISPR
Overview
Concept behind CRISPR/CAS:
- Part of the adaptive microbial immune system
- Clustered Regularly Interspaced Short Palindromic Repeats
- Family of DNA repeats found in:
o 90% of Archaea
o 40% of Bacteria
- Initially thought of as junk DNA
- Is a ‘memory of past genetic aggressions’
o i.e. showed what viruses and plasmids and phages the bacteria had been
exposed to in the past.
- Provides adaptive immunity – the removal/addition of CRISPR spacer sequences can
affect resistance to phage attack.
- CRISPR array associated with cas genes
- Array:
o Leader:
AT rich
Contains CRISPR promoter
o Spacers:
Variable sequences of similar length
17-100bp; 36bp average
o Repeats:
Invariable sequence except the terminal repeat
Partially palindromic
23-50bp
Forms stem loop
Features:
- Incorporation of Foreign DNA
o CRISPR/Cas system has ability to incorporate short sequences of foreign
DNA known as spacers
o Cas proteins incorporate new DNA by cutting it up and adding it to the
assay.
- Adaptive or Acquired Immunity
o Spacers transcribed into small non-coding RNAs (cRNA which is
complementary to incoming phage DNA) which in conjunction with Cas
protein complexes target and bind to incoming foreign DNA destroying it.
o Sequence-specific recognition process results in destruction of incoming
foreign DNA
- Heritable Immunity
o CRISPR/Cas system can readily acquire new spacers (or lose old ones)
which allows it to respond dynamically to a viral predator which evolves
at higher rates.
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper mattclothier13. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €6,61. Je zit daarna nergens aan vast.